Table 1.
Clinical characteristics and admission labs overall and by sex in the CUIMC/NYP COVID-19 cohort.
| Overall (N = 2,626) | Male (N = 1,497) | Female (N = 1,129) | P-value* | |
|---|---|---|---|---|
| Presentation to care | ||||
| Age in years (median [IQR]) | 66 (54, 77) | 64 (53, 75) | 69 (57, 80) | <0.001 |
| Age ≥65 years | 1,420/2,626 (0.54) | 748/1,497 (0.50) | 672/1,129 (0.60) | <0.001 |
| White/non-Hispanic | 237/2,626 (0.09) | 139/1,497 (0.09) | 98/1,129 (0.09) | 0.6406 |
| Black/non-Hispanic | 320/2,626 (0.12) | 180/1,497 (0.12) | 140/1,129 (0.12) | 0.8169 |
| Hispanic | 1,314/2,626 (0.50) | 747/1,497 (0.50) | 567/1,129 (0.50) | 0.9015 |
| Other | 755/2,626 (0.29) | 431/1,497 (0.29) | 324/1,129 (0.29) | 0.9932 |
| Fever | 604/2,624 (0.23) | 371/1,497 (0.25) | 233/1,127 (0.21) | 0.0152 |
| Body mass index (Median [IQR]) | 28.02 (24.60, 32.66) | 27.46 (24.36, 31.46) | 28.96 (24.89, 34.13) | <0.001 |
| On statins | 951/2,626 (0.36) | 519/1,497 (0.35) | 432/1,129 (0.38) | 0.0634 |
| On ACEi or ARBs† | 442/2,626 (0.17) | 238/1,497 (0.16) | 204/1,129 (0.18) | 0.1559 |
| Co-morbidities | ||||
| Obesity‡ | 794/2,113 (0.38) | 393/1,219 (0.32) | 401/894 (0.45) | <0.001 |
| Coronary artery disease | 329/2,626 (0.13) | 204/1,497 (0.14) | 125/1,129 (0.11) | 0.0576 |
| Hypertension | 1,430/2,626 (0.54) | 779/1,497 (0.52) | 651/1,129 (0.58) | 0.0047 |
| Diabetes mellitus type 2 | 968/2,626 (0.37) | 553/1,497 (0.37) | 415/1,129 (0.37) | 0.9561 |
| Chronic kidney disease | 370/2,626 (0.14) | 219/1,497 (0.15) | 151/1,129 (0.13) | 0.3908 |
| Lung disease | 463/2,626 (0.18) | 207/1,497 (0.14) | 256/1,129 (0.23) | <0.001 |
| Cancer | 261/2,626 (0.10) | 155/1,497 (0.10) | 106/1,129 (0.09) | 0.4517 |
| Heart failure | 275/2,626 (0.10) | 149/1,497 (0.10) | 126/1,129 (0.11) | 0.3494 |
| Stroke | 225/2,626 (0.09) | 130/1,497 (0.09) | 95/1,129 (0.08) | 0.8620 |
| Admission labs (median [IQR]) § | ||||
| hs-CRP (mg/L; n = 2,414) | 118.46 (56.79, 205.18) | 130.48 (63.66, 215.36) | 105.79 (45.40, 184.04) | <0.001 |
| D-Dimer (ng/mL; n = 2,179) | 1,510 (830, 3,290) | 1,490 (800, 3,440) | 1,520 (873, 3,170) | 0.6767 |
| Ferritin (ng/mL; n = 2,391) | 702.6 (345.40, 1,293) | 870.4 (457.80, 1584.50) | 479.4 (238.80, 929.60) | <0.001 |
| Creatinine (mg/dL; n = 2,609) | 1.07 (0.81, 1.64) | 1.17 (0.91, 1.75) | 0.92 (0.70, 1.48) | <0.001 |
| hs-cTnT (ng/L; n = 2,402) | 17 (8, 42) | 19 (9, 43) | 16 (8, 39) | 0.0028 |
*
P-values correspond to a two-sample test of proportions (for categorical variables) or Wilcoxon rank sum tests (for numeric variables) comparing corresponding characteristics of male vs. female patients;
†
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
‡
Obesity is defined as BMI ≥30 and is missing for 513 patients;
§
Admission labs - recorded within +/-3 days of hospital admission.
IQR, interquartile range; hs-CRP, high sensitivity C-reactive protein; hs-cTNT, high sensitivity cardiac Troponin T.